Edwards +3.7% AH; FDA approves Sapien XT valve


The FDA has approved Edwards' (EW) Sapien XT transcatheter aortic heart valve for "the treatment of high-risk and inoperable patients suffering from severe symptomatic aortic stenosis."

The low-profile valve, available in Europe since 2010 and Japan since 2013, will now be available to U.S. patients "at leading cardiovascular centers across the nation." Edwards predicts it will increase the number of treatable patients.

Previous: Sapien XT beats Medtronic device in study

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs